Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Belgium is TOP biotech non-US hotspot

Genengnews, the US news agency for Genetic Engineering & Biotechnology, published a list of 12 non-US hotspots for biotechnology jobs. Belgium is …


CEO FLUIDDA wins Antwerp Young Enterpreneur of the Year prize

This year marked the 6th edition of the Antwerp Young Enterpreneur competition, highlighting the entrepreneurial spirit in the province’s younger …


AbbVie in top 10 Best Workplaces 2016

On March 15th, the Best Workplaces of 2016 in Belgium were awarded. AbbVie, as the sole biopharmaceutical company, ranks in the top 10. In a n…

POPULAR TAGS

Indian Patent Office overturns Sovaldi ruling

Written by LVS on in the category news with the tags .


The Indian Patent Office of New Delhi granted Gilead Sciences Inc. (NASDAQ:GILD) a patent covering active metabolites of HCV drug Sovaldi sofosbuvir, reversing an earlier ruling .

In Monday's decision, Deputy Controller of Patents & Designs Rajesh Dixit said the claimed compounds are "novel, inventive and patentable," and that prior art presented by opponents to the application relied on "hypothetical compounds" that a person skilled in the art would not be able to synthesize without the advantage of hindsight. Optimus Pharma Ltd. (Hyderabad, India) and BRD Pharmaceuticals International Pvt. Ltd. (Mumbai, India) argued against awarding the patent, as did the SanKalp Rehabilitation Trust, the India Cares Foundation, Delhi Network of Positive People (DNP+) and the Initiative for Medicines Access & Knowledge (I-MAK).

In a January 2015 decision rejecting Gilead's patent application, the office found that Sovaldi did not offer "significantly enhanced therapeutic efficacy as compared to the nearest prior art molecule which is structurally and functionally close." The High Court of Delhi remanded the decision later that month.

In a statement on Tuesday, Gilead said it "believes that, if used responsibly, IP does not hinder access" to medicines. In September 2014, the company granted non-exclusive rights to seven Indian generics companies to manufacture Sovaldi and Harvoni sofosbuvir/ledipasvir for distribution in 91 developing countries.

Adapted from BioCentury.

Read more about: .

RELATED ARTICLES
Belgium is TOP biotech non-US hotspot

Genengnews, the US news agency for Genetic Engineering & Biotechnology, published a list of 12 non-US hotspots for biotechnology jobs. Belgium is …


CEO FLUIDDA wins Antwerp Young Enterpreneur of the Year prize

This year marked the 6th edition of the Antwerp Young Enterpreneur competition, highlighting the entrepreneurial spirit in the province’s younger …


AbbVie in top 10 Best Workplaces 2016

On March 15th, the Best Workplaces of 2016 in Belgium were awarded. AbbVie, as the sole biopharmaceutical company, ranks in the top 10. In a n…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Biowin GSK KU Leuven UGent Itera Life Science XpandInnovation Flanders.bio V-Bio Ventures Janssen Turnstone

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.